Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation.
BACKGROUND
Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) are established causes of HCC. HCC patients are often diagnosed late and receive palliative therapies, however, the survival of Asian American patients with HCC treated without transplantation has not been well studied. We reviewed our institution's experience to determine predictors and rates of survival in Asian American HCC patients treated without transplantation.


METHODS
We identified Asian American patients with HCC referred to M. D. Anderson Cancer Center. Patients were tested for HBV and HCV. Survival curves were generated by Kaplan-Meier method. Multivariate Cox proportional hazards regression was used to test the relationship between prognostic factors and survival.


RESULTS
Of 82 Asian American HCC patients, most had advanced disease (65%) and received treatment (68%); however, only 11% had surgical resection. 94% had positive anti-HBc and 61% had positive HBsAg. 20% had positive anti-HCV. There were no significant changes in the rates of HBV and HCV over time. Male gender, high alpha-fetoprotein levels, and stage IV disease were associated with shorter survival Overall median survival was 9.2 months (95% CI 6.5-11.9), and the survival of HCV and HBV patients was not statistically different.


CONCLUSIONS
The survival rate of Asian American patients with advanced HCC, for whom transplantation was not available, was low. Timely hepatitis screening and interventions by primary care physicians may be the most logical solution to reduce the burden of hepatitis-associated HCC among Asian Americans.
Hwang
Jessica P
JP
Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jphwang@mdanderson.org
Hassan
Manal M
MM
D000328:Adult; D000368:Aged; D001213:Asian; D006528:Carcinoma, Hepatocellular / Q000208:ethnology* / Q000401:mortality* / Q000628:therapy / Q000821:virology; D005260:Female; D006505:Hepatitis / Q000150:complications* / Q000821:virology; D006801:Humans; D016031:Liver Transplantation / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors; D013534:Survival; D000509:alpha-Fetoproteins / Q000378:metabolism
D000509:alpha-Fetoproteins